Adagene (ADAG) Total Non-Current Liabilities (2019 - 2026)

Adagene (ADAG) posted quarterly Total Non-Current Liabilities of -$205.1 billion for Q4 2025, down 529515.03% year-over-year from N/an in Q4 2024, and down 717177.32% quarter-over-quarter from $28.6 million in Q2 2025.

Adagene (ADAG) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends

Adagene (ADAG) has reported Total Non-Current Liabilities for 7 consecutive years, with -$205.1 billion the latest figure, recorded in Q4 2025.

  • In Q4 2025, Total Non-Current Liabilities fell 529515.03% year-over-year to -$205.1 billion; the TTM figure through Dec 2025 stood at -$205.1 billion (down 529515.03% YoY), while the FY2025 annual figure was -$205.1 billion, down 529515.03% from the prior year.
  • Total Non-Current Liabilities eased to -$205.1 billion in Q4 2025 per ADAG's latest filing, from $28.6 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $45.2 million in Q4 2023 and bottomed at -$205.1 billion in Q4 2025.
  • Historically, Total Non-Current Liabilities has averaged -$29.1 billion across 5 years, with a median of $30.1 million in 2021.
  • Annual changes were most pronounced in 2024 — Total Non-Current Liabilities surged 100.16% — and 2025, when it slumped 529515.03%.
  • Adagene's Total Non-Current Liabilities stood at $32.9 million in 2021, then slumped by 87289.64% to -$28.6 billion in 2022, then surged by 100.16% to $45.2 million in 2023, then fell by 14.22% to $38.7 million in 2024, then plunged by 529515.03% to -$205.1 billion in 2025.
  • Business Quant data shows ADAG's Total Non-Current Liabilities at -$205.1 billion in Q4 2025, $28.6 million in Q2 2025, and $38.7 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 40.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 1.53 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 1.88 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 9.32 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 4.20 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 1.17 Bn
10 Adagene 310.54 Mn 310.54 Mn - 26.39 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 26.39 Mn
Dec 31, 2025 -205.12 Bn
Jun 30, 2025 28.60 Mn
Dec 31, 2024 38.74 Mn
Jun 30, 2024 44.19 Mn
Dec 31, 2023 45.17 Mn
Jun 30, 2023 -27.68 Bn
Dec 31, 2022 -28.65 Bn
Jun 30, 2022 -29.80 Bn
Dec 31, 2021 32.86 Mn
Jun 30, 2021 31.58 Mn
Dec 31, 2020 19.11 Mn
Dec 31, 2019 8.70 Mn